Rasio Nilai Pasar marang Nilai Buku: Karyopharm Therapeutics Inc. (KPTI)

KPTI (Karyopharm Therapeutics, Inc.) - tandha merek perusahaan

Karyopharm Therapeutics (KPTI) ensures the seamless delivery of targeted agents through an extensive warehouse network, which supports high operational margins. A monopoly position in myeloma therapy driven by patents allows the company to exercise pricing power, with treatment costs currently at -0.06. The available price action complements the picture of an active expansion of the SINE-inhibitor pipeline and the preparation of new Selinexor releases.

Rasio Kapitalisasi marang Nilai Buku karyopharm.com (KPTI): kanggo periode 04.07.2022 - 30.10.2026

Rincian analitis perusahaan Karyopharm Therapeutics

- rega saham lan prakiraan rega para ahli:
Rega saham karyopharm.com|KPTI - Target median analis
- indikator kapitalisasi bursa perusahaan:
Nilai pasar Karyopharm|KPTI - Total Nilai Perusahaan
- data kapitalisasi buku:
Aset Bersih saben Siji Saham Karyopharm Therapeutics|KPTI - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku karyopharm.com|KPTI - Gunggung Aset Perusahaan
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas Karyopharm Therapeutics|KPTI - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas karyopharm.com|KPTI - Utang perusahaan|Rasio utang marang kapitalisasi buku Karyopharm|KPTI - Utang jangka dawa|Utang jangka cendhak perusahaan Karyopharm Therapeutics|Indikator likuiditas cepet karyopharm.com
- rincian bathi lan kelipatan pasar:
KPTI - Penghasilan resik perusahaan
Pambiji fundamental:Karyopharm Therapeutics
Produk asil prodhuksi karyopharm.com

Stable cash flow from sales of the antineoplastic drug allows Karyopharm Therapeutics (KPTI) to effectively fund R&D developments. By analyzing the price-to-book ratio trend, an investor can see the current market valuation of net assets. This metric compares market capitalization with the book value of equity. A significant premium in this ratio signals inflated market expectations. Understanding this gap is critical for minimizing the risks of a deep portfolio drawdown.

Analisis perusahaan pesaing

GMAB: Rasio Kapitalisasi Pasar marang Nilai Buku|EXEL - Kapitalisasi Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Nuvalent|Koefisien Nilai Pasar marang Nilai Buku Kymera Therapeutics, Inc. KYMR|Rasio Nilai Pasar marang Nilai Buku IDEAYA Bio (IDYA)|Enliven Corp - Rasio Kapitalisasi marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku ORIC (ORIC Pharmaceuticals)|RLAY - Rasio Kapitalisasi marang Aset Bersih|NRIX - Rasio Nilai Pasar marang Nilai Buku|Koefisien Nilai Pasar marang Nilai Buku Tyra Biosciences Inc|Verastem Inc (VSTM) - Rasio Nilai Pasar marang Nilai Buku|GLUE (Monte Rosa Corp) - Rasio Nilai Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Cullinan Therapeutics|Koefisien Nilai Pasar marang Nilai Buku immuneering.com IMRX|Rasio Kapitalisasi Pasar marang Nilai Buku CCCC|Black Diamond Therapeutics, Inc. (BDTX) - Rasio Nilai Pasar marang Ekuitas|Repare Rx - Rasio Kapitalisasi marang Aset Bersih|PMV Pharmaceuticals, Inc (PMVP) - Koefisien Nilai Pasar marang Nilai Buku|PPCB: Rasio Kapitalisasi marang Aset Bersih|Nilai Pasar marang Nilai Buku BGMS (cyclacel.com)|AADI (aadibio.com) - Rasio Kapitalisasi marang Aset Bersih|ALRN: Multiplikator Kapitalisasi Pasar marang Nilai Buku|BPMC (Blueprint Medicines Corp.) - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku GlycoMimetics Corp|Rasio Nilai Pasar marang Nilai Buku SpringWorks Therapeutics (SWTX)